SELL Aurobindo Pharma — Macquarie, 06 Aug 2026

SELLAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byMacquarieHorizon: NA (inferred 1 year)6 Aug 2026via CNBC Awaaz.

Entry₹1,625Inferred

Target₹1,300

Total upside +20.00%

Stop lossNot given

CMP₹1,610.91h ago

Active+0.87%+19.30%upside left 10 mo left

Follow Macquarie for new calls(100% target hit, 13 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 10 other Long-term calls on AUROPHARMA See 211 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 5:33 pm IST

7 supporting18 neutral53 opposing

Supports the SELL call (7)

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·27 Jul · 3mo ago

Neutral / worth noting (18)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3d ago

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 2w ago

Aurobindo Pharma Ltd has announced the acquisition of a step-down subsidiary located in the USA.

BSE · Company Update·2 Oct · 3w ago

Weighs against the SELL call (53)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·21 Oct · yesterday

5 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·7 Oct · 2w ago

Aurobindo Pharma Shares in Focus After USFDA Approval for Perampanel

NewsGoogle News·5 Oct · 2w ago

Aurobindo Pharma USFDA Approval Sparks Rally to New 52-Week High

NewsGoogle News·5 Oct · 2w ago

Aurobindo Pharma rises on getting USFDA`s final nod to manufacture, market Perampanel tablets

NewsGoogle News·5 Oct · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Macquarie

Every call and its outcome